IMPAKT Breast Cancer Conference
"The presentations at this year's IMPAKT reveal the innovative and diverse approaches that investigators are taking to identify the most encouraging new agents both before clinical evaluation and in early clinical studies. These range from ideas for novel clinical designs to the development of more sensitive and specific biomarkers and to data sharing that allows a more objective assessment of compounds prior to commitment of major clinical resources."
Mitchell Dowsett, IMPAKT 2011 Scientific Chair
The IMPAKT Press Program will feature new study results from the conference program about how better understanding of the genetic and molecular underpinning of individual women's cancers can help guide treatment:
- Largest study of its kind so far validates prognostic value of circulating tumor cells in breast cancer
- Epigenetics may help improve management for breast cancer patients
- Validating gene tests for prognosis in early-stage breast cancer
- Combining protein and gene testing methods for predicting breast cancer drug response
- New predictive marker identified in triple-negative breast cancer
- Anti-inflammatory drug: promising treatment option for breast cancer
- 3 keynote lectures
- 2 special educational sessions
- Best Abstract session
- Poster Walk session
Highlights on:
- Genomic data: how to make good use of mountains of data
- Clinically challenging breast cancer sub-types: identification and clinical solutions
- Her2 testing: towards a common language between pathologists and clinicians
- Pre-operative therapy: a faster route to the clinic for new therapeutics?
- Breast cancer genomes: making sense of complexity
- Pharmacogenetics: what have we learnt? Hope of hype from the clinician's point of view?
- Blood biomarkers: is there a future?
- Tumor genotyping at the front door - already a reality
The full conference program is available at http://www.esmo.org/events/breast-2011-impakt/program.html
Press conference
Thursday, 5 May 2011, 12:00-13:00 (CEST)
Hosts:
Martine Piccart, Head of Chemotherapy Unit, Jules Bordet Institute in Brussels, Belgium, IMPAKT Co-Founder
Mitchell Dowsett, Breakthrough Research Centre, Royal Marsden Hospital, London, UK, IMPAKT2011 Scientific Chair
Nadia Harbeck, Frauenklinik, University of Cologne, Cologne, Germany, IMPAKT2011 Executive Chair
Topics:
- Advances in genetics and epigenetics to predict how patients will respond to particular treatments
- Potential new exciting targets for breast cancer therapy
- New therapies in development, some will make it to the clinic, others won't: general approaches and specific therapeutics
Journalists will be able to attend the press conference both in person and remotely through toll-free dial-in.
Journalists will also be able to schedule one-on-one interviews with presenters of the studies and key experts, both in person and remotely.
Please contact the IMPAKT Press Office at media@esmo.org to book your telephone hook-up, to schedule your interviews and/or register for the event.
All sessions are open to journalists and registration is free to bona fide journalists on presentation of a valid press card and a letter of assignment.
A Press room, located in the Lounge on the mezzanine next to the Gold Hall and equipped with resources and technical facilities, is open to journalists registered for the Conference.
Provided by European Society for Medical Oncology
